Clinical Trials

Open label study of subcutaneous immunoglobulin in myasthenia gravis

Myasthenia gravis patients receiving intravenous immunoglobulin (IVIg) for maintenance therapy will be switched over to subcutaneous immunoglobulin (SCIg) for a 3 month period of time.

To assess safety and efficacy of SCIg in myasthenia gravis.

Eligibility

As under requirements

Requirements

MG patients with either AChR or MuSK antibodies, stable on IVIg therapy for three cycles prior to entry

Reimbursement

None

Investigator

Nicholas J. Silvestri, Gil I. Wolfe

Contact Information

Name: Connie Brand
Phone: 716-859-7620
Email: conniebr@buffalo.edu